A detailed history of Two Sigma Investments, LP transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Investments, LP holds 151,391 shares of CLDX stock, worth $5.6 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
151,391
Holding current value
$5.6 Million
% of portfolio
0.02%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$35.22 - $51.88 $5.33 Million - $7.85 Million
151,391 New
151,391 $6.35 Million
Q2 2023

Aug 14, 2023

SELL
$30.29 - $38.28 $201,761 - $254,983
-6,661 Reduced 26.55%
18,423 $625,000
Q1 2023

May 15, 2023

BUY
$34.78 - $47.43 $872,421 - $1.19 Million
25,084 New
25,084 $902,000
Q3 2022

Nov 14, 2022

SELL
$22.7 - $37.57 $5.54 Million - $9.16 Million
-243,840 Reduced 89.12%
29,780 $837,000
Q2 2022

Aug 15, 2022

BUY
$20.5 - $37.33 $915,776 - $1.67 Million
44,672 Added 19.51%
273,620 $7.38 Million
Q1 2022

May 16, 2022

BUY
$27.64 - $39.32 $975,885 - $1.39 Million
35,307 Added 18.23%
228,948 $7.8 Million
Q4 2021

Feb 14, 2022

BUY
$35.68 - $56.27 $6.91 Million - $10.9 Million
193,641 New
193,641 $7.48 Million
Q1 2021

May 17, 2021

SELL
$16.19 - $29.91 $3.19 Million - $5.89 Million
-196,792 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$14.99 - $22.75 $2.9 Million - $4.39 Million
-193,150 Reduced 49.53%
196,792 $3.45 Million
Q3 2020

Nov 16, 2020

BUY
$9.65 - $15.19 $2.5 Million - $3.93 Million
258,848 Added 197.45%
389,942 $5.78 Million
Q2 2020

Aug 14, 2020

BUY
$1.61 - $13.41 $211,061 - $1.76 Million
131,094 New
131,094 $1.7 Million
Q3 2019

Nov 14, 2019

SELL
$2.05 - $2.75 $70,331 - $94,347
-34,308 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$2.43 - $5.09 $83,368 - $174,627
34,308 New
34,308 $92,000

Others Institutions Holding CLDX

About Celldex Therapeutics, Inc.


  • Ticker CLDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,772,400
  • Market Cap $1.73B
  • Description
  • Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...
More about CLDX
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.